Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 Mar 2020
Historique:
received: 10 03 2020
revised: 24 03 2020
accepted: 28 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 5 1 2021
Statut: epublish

Résumé

The majority of chemotherapeutic agents stimulate NF-κB signaling that mediates cell survival, proliferation and metastasis. The natural turmeric non-curcuminoid derivate Calebin A has been shown to suppress cell growth, invasion and colony formation in colorectal cancer cells (CRC) by suppression of NF-κB signaling. Therefore, we hypothesized here that Calebin A might chemosensitize the TNF-β-treated tumor cells and potentiates the effect of 5-Fluorouracil (5-FU) in advanced CRC. CRC cells (HCT116) and their clonogenic 5-FU chemoresistant counterparts (HCT116R) were cultured in monolayer or alginate-based 3D tumor environment culture and were treated with/without Calebin A, TNF-β, 5-FU, BMS-345541 and DTT (dithiothreitol). The results showed that TNF-β increased proliferation, invasion and resistance to apoptosis in chemoresistant CRC cells. Pretreatment with Calebin A significantly chemosensitized HCT116R to 5-FU and inhibited the TNF-β-induced enhanced efforts for survival, invasion and anti-apoptotic effects. We found further that Calebin A significantly suppressed TNF-β-induced phosphorylation and nuclear translocation of p65-NF-κB, similar to BMS-345541 (specific IKK inhibitor) and NF-κB-induced tumor-promoting biomarkers (NF-κB, β1-Integrin, MMP-9, CXCR4, Ki67). This was associated with increased apoptosis in HCT116 and HCT116R cells. Furthermore, blocking of p65-NF-κB stimulation by Calebin A was imparted through the downmodulation of p65-NF-κB binding to the DNA and this suppression was turned by DTT. Our findings indicate, for the first time, that Calebin A chemosensitizes human CRC cells to chemotherapy by targeting of the p65-NF-κB signaling pathway.

Identifiants

pubmed: 32244288
pii: ijms21072393
doi: 10.3390/ijms21072393
pmc: PMC7177530
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0
Cinnamates 0
Lymphotoxin-alpha 0
Monoterpenes 0
NF-kappa B 0
RELA protein, human 0
Transcription Factor RelA 0
calebin-A 0
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Cancer Sci. 2007 Mar;98(3):268-74
pubmed: 17270016
Oncogene. 2015 Jul;34(27):3493-503
pubmed: 25174402
Biomedicines. 2018 Apr 17;6(2):
pubmed: 29673148
Biochem Pharmacol. 2015 Nov 1;98(1):51-68
pubmed: 26310874
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Front Biosci. 2008 May 01;13:5094-107
pubmed: 18508572
Clin Cancer Res. 2008 Apr 1;14(7):2128-36
pubmed: 18381954
J Biol Chem. 2006 Jun 23;281(25):17023-33
pubmed: 16624823
Int J Oncol. 2009 Apr;34(4):1117-28
pubmed: 19287970
Cancer Lett. 2018 Mar 1;416:75-86
pubmed: 29246645
J Mol Med (Berl). 2004 Jul;82(7):434-48
pubmed: 15175863
Pharmaceutics. 2019 Oct 04;11(10):
pubmed: 31590262
Nutrients. 2018 Jul 12;10(7):
pubmed: 30002278
Front Biosci (Schol Ed). 2009 Jun 01;1:45-60
pubmed: 19482682
Nutrients. 2017 Sep 27;9(10):
pubmed: 28953264
Oncotarget. 2016 May 31;7(22):31892-906
pubmed: 26895469
Front Immunol. 2018 Nov 22;9:2585
pubmed: 30524422
Exp Biol Med (Maywood). 2019 Jan;244(1):1-12
pubmed: 30661394
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Curr Mol Med. 2007 Nov;7(7):619-37
pubmed: 18045141
Arch Biochem Biophys. 2016 Mar 1;593:80-9
pubmed: 26874195
J Pathol Clin Res. 2018 Apr;4(2):124-134
pubmed: 29665320
J Mol Med (Berl). 2009 Nov;87(11):1097-104
pubmed: 19727638
Biotechnol Adv. 2014 Nov 1;32(6):1053-64
pubmed: 24793420
PLoS One. 2013 Jul 16;8(7):e69760
pubmed: 23874993
Anticancer Res. 2010 Feb;30(2):319-25
pubmed: 20332435
PLoS One. 2013;8(2):e57218
pubmed: 23451189
Gastroenterology. 2010 Jun;138(6):2151-62
pubmed: 20420952
J Biol Chem. 2001 Oct 26;276(43):39713-20
pubmed: 11500489
Int J Cancer. 2019 Sep 1;145(5):1358-1370
pubmed: 30785217
Trends Biochem Sci. 2005 Jan;30(1):43-52
pubmed: 15653325
Arch Biochem Biophys. 2014 Oct 1;559:91-9
pubmed: 24946050
Curr Opin Pharmacol. 2009 Aug;9(4):351-69
pubmed: 19665429
BMC Cancer. 2015 Apr 10;15:250
pubmed: 25884903
Biochem Pharmacol. 2006 Feb 28;71(5):634-45
pubmed: 16360644
Nutr Cancer. 2009;61(6):842-6
pubmed: 20155625
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
Biochem Pharmacol. 2010 May 1;79(9):1272-80
pubmed: 20067776
Curr Opin Pharmacol. 2006 Aug;6(4):337-44
pubmed: 16777480
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9090-5
pubmed: 8799159
Cancer Treat Rev. 2009 Aug;35(5):451-62
pubmed: 19467788
Clin Sci (Lond). 2017 Jul 5;131(15):1781-1799
pubmed: 28679846
J Basic Clin Physiol Pharmacol. 2018 Mar 28;29(2):107-122
pubmed: 29389665
J Biol Chem. 1984 Jan 10;259(1):686-91
pubmed: 6608523
Curr Pharm Biotechnol. 2011 Apr;12(4):609-20
pubmed: 21118092
Mol Cancer Ther. 2014 Oct;13(10):2422-35
pubmed: 25082961
Oncogene. 2007 Mar 1;26(10):1385-97
pubmed: 16953224
Genes Cells. 2008 May;13(5):509-20
pubmed: 18429822
J Clin Oncol. 2019 Nov 20;37(33):3111-3123
pubmed: 31593484
Biomed Pharmacother. 2014 Oct;68(8):911-6
pubmed: 25458789
Immunobiology. 2009;214(9-10):761-77
pubmed: 19616341
Nat Struct Biol. 1998 Jan;5(1):67-73
pubmed: 9437432
J Oncol Pharm Pract. 2018 Oct;24(7):501-506
pubmed: 28714378
Oncologist. 2006 Oct;11(9):973-80
pubmed: 17030637
Biochemistry. 2009 Aug 4;48(30):7271-8
pubmed: 19591457
Front Immunol. 2018 Sep 27;9:2160
pubmed: 30319623
J Biol Chem. 1985 Feb 25;260(4):2345-54
pubmed: 3871770
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Int J Mol Sci. 2019 Oct 09;20(20):
pubmed: 31600949
Arch Pharm Res. 2018 Jan;41(1):1-13
pubmed: 29230689
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889-2895
pubmed: 26528921
Onco Targets Ther. 2018 Apr 11;11:2063-2073
pubmed: 29695914
Nutrients. 2019 Dec 01;11(12):
pubmed: 31805741
Mol Pharmacol. 2011 Nov;80(5):769-81
pubmed: 21795584
Blood. 2019 Mar 28;133(13):1489-1494
pubmed: 30696620
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Oncol. 2009 Dec;2(4):321-8
pubmed: 19956394
Phytomedicine. 2017 Oct 15;34:171-181
pubmed: 28899500
J Clin Pathol. 2018 Feb;71(2):110-116
pubmed: 28942428
Eur J Pharmacol. 2008 Sep 4;591(1-3):252-8
pubmed: 18619958
Oncologist. 2018 May;23(5):573-579
pubmed: 29371477
Nutrients. 2019 Mar 26;11(3):
pubmed: 30917533
Cell Stem Cell. 2007 Oct 11;1(4):389-402
pubmed: 18371377
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Mol Nutr Food Res. 2013 Sep;57(9):1529-42
pubmed: 23847105
Blood. 2003 Feb 1;101(3):1053-62
pubmed: 12393461
Oncol Lett. 2019 Dec;18(6):6869-6876
pubmed: 31807190

Auteurs

Constanze Buhrmann (C)

Musculoskeletal Research Group and Tumour Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany.

Ajaikumar B Kunnumakkara (AB)

Cancer Biology Laboratory & DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences & Bioengineering, Indian Institute of Technology Guwahati, Assam 781039, India.

Bastian Popper (B)

Biomedical Center, Core facility animal models, Ludwig-Maximilian-University Munich, D-82152 Martinsried, Germany.
Institute of Pathology, School of Medicine, Technical University of Munich, D-81675 Munich, Germany.

Muhammed Majeed (M)

Sabinsa Corporation, East Windsor, NJ 08520, USA.

Bharat B Aggarwal (BB)

Inflammation Research Center, San Diego, CA 92126, USA.

Mehdi Shakibaei (M)

Musculoskeletal Research Group and Tumour Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH